Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29322848 | 0.85 | KMT2A (0.51) | MEN1KMT2ACYP3A4ACHEALDH1A1 | |
| SCHEMBL30179164 | 0.84 | MEN1 (0.48) | MEN1KMT2ACYP3A4ALDH1A1HTR1A | |
| SCHEMBL29324429 | 0.84 | MEN1 (0.48) | MEN1KMT2ACYP3A4ALDH1A1HTR1A | |
| SCHEMBL5955654 | 0.78 | ADAM17 (0.58) | CYP3A4ALDH1A1L3MBTL1ADAM17 | |
| SCHEMBL4079920 | 0.78 | MEN1 (0.54) | MEN1KMT2ACYP3A4ACHEALDH1A1 | |
| SCHEMBL12676327 | 0.78 | MEN1 (0.48) | MEN1KMT2AALDH1A1HTR1ADRD4 | |
| SCHEMBL29630709 | 0.78 | ACHE (0.48) | CYP3A4ACHEDRD4 | |
| SCHEMBL11923833 | 0.76 | MEN1 (0.70) | MEN1KMT2ACYP3A4ACHEALDH1A1 | |
| SCHEMBL28644853 | 0.76 | LRRK2 (0.42) | MEN1KMT2ADRD3ADAM17 | |
| SCHEMBL10200126 | 0.75 | KMT2A (0.42) | MEN1KMT2ACYP3A4ALDH1A1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569336-B2 | Compounds for the treatment of inflammatory disorders | TONG LING (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TONG LING (US) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015926-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | MEN1 1657/4885KMT2A 4253/4885CYP3A4 2754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.